Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9Y2V0

UPID:
CDIN1_HUMAN

ALTERNATIVE NAMES:
Protein HH114

ALTERNATIVE UPACC:
Q9Y2V0; B2RD87

BACKGROUND:
The role of CDAN1-interacting nuclease 1 in the differentiation of erythroid cells positions it as a critical factor in the production of red blood cells. Known alternatively as Protein HH114, its function is integral to the proper development and function of erythrocytes, which are essential for oxygen transport in the body.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of CDAN1-interacting nuclease 1 could open doors to potential therapeutic strategies for treating congenital dyserythropoietic anemia, 1B. This condition, characterized by abnormal erythroblast morphology and ineffective erythropoiesis, could benefit from targeted therapies aimed at the molecular mechanisms involving CDAN1-interacting nuclease 1.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.